Analyst Price Targets — CDTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 14, 2025 9:13 pm | — | RBC Capital | $221.50 | $217.71 | TheFly | Cidara downgraded to Sector Perform from Outperform at RBC Capital |
| October 9, 2025 2:44 pm | Sara Nik | H.C. Wainwright | $150.00 | $108.18 | TheFly | Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright |
| October 3, 2025 9:40 am | — | JMP Securities | $173.00 | $98.50 | TheFly | Cidara Therapeutics price target raised to $173 from $153 at Citizens JMP |
| September 26, 2025 10:06 am | — | H.C. Wainwright | $110.00 | $86.60 | TheFly | Cidara Therapeutics price target raised to $110 from $74 at H.C. Wainwright |
| September 24, 2025 5:09 pm | Roy Buchanan | JMP Securities | $153.00 | $88.32 | TheFly | Cidara Therapeutics price target raised to $153 from $66 at Citizens JMP |
| September 24, 2025 2:14 pm | Seamus Fernandez | Guggenheim | $167.00 | $86.68 | TheFly | Cidara Therapeutics price target raised to $167 from $70 at Guggenheim |
| September 24, 2025 1:23 pm | Brian Abrahams | RBC Capital | $137.00 | $88.58 | TheFly | Cidara Therapeutics price target raised to $137 from $115 at RBC Capital |
| July 9, 2025 12:22 pm | Seamus Fernandez | Guggenheim | $69.00 | $50.96 | StreetInsider | Cidara Therapeutics (CDTX) PT Raised to $69 at Guggenheim |
| June 24, 2025 11:39 am | — | Guggenheim | $68.00 | $46.84 | TheFly | Cidara Therapeutics price target raised to $68 from $50 at Guggenheim |
| May 16, 2025 12:33 pm | Seamus Fernandez | Guggenheim | $50.00 | $25.50 | TheFly | Cidara Therapeutics price target raised to $50 from $35 at Guggenheim |
Latest News for CDTX
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) shares crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $220.52 and traded as high as $221.41. Cidara Therapeutics shares last traded at $221.38, with a volume of 2,691,000 shares. Analysts Set New Price Targets CDTX has
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
ANB Bank bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 3,187 shares of the biotechnology company's stock, valued at approximately $305,000. Several other institutional investors and hedge funds also recently made changes to
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has assigned
HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.79 million. The position represents 1.66% of 13F reportable assets under management (AUM).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CDTX.
U.S. House Trading
No House trades found for CDTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.